Clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrence

The main focus of the current work was to design, evaluate and clinically compare the efficiency of novel metronidazole (MTD) loaded solid lipid nanoparticles (SLNs) vaginal emulgel with the marketed vaginal gel (Metron®) against Bacterial vaginosis (BV). Eight formulations were fabricated using 23...

Full description

Bibliographic Details
Main Authors: Noha M. Badawi, Mona A. Elkafrawy, Rania M. Yehia, Dalia A. Attia
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Drug Delivery
Subjects:
Online Access:http://dx.doi.org/10.1080/10717544.2021.1912211
id doaj-f4ef6d8292574eff83c4404cc760feae
record_format Article
spelling doaj-f4ef6d8292574eff83c4404cc760feae2021-05-06T15:44:45ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642021-01-0128181482510.1080/10717544.2021.19122111912211Clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrenceNoha M. Badawi0Mona A. Elkafrawy1Rania M. Yehia2Dalia A. Attia3Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The British University in Egypt (BUE)Department of Obstetrics and Gynecology, Faculty of Medicine (Girls), Al-Azhar UniversityDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The British University in Egypt (BUE)Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The British University in Egypt (BUE)The main focus of the current work was to design, evaluate and clinically compare the efficiency of novel metronidazole (MTD) loaded solid lipid nanoparticles (SLNs) vaginal emulgel with the marketed vaginal gel (Metron®) against Bacterial vaginosis (BV). Eight formulations were fabricated using 23 full factorial design and prepared by stearic acid and tween 80 as solid lipid and surfactant, respectively. Lipid and surfactant concentrations in addition to sonication amplitude were chosen as the independent variables (X1–X3). Then, the prepared MTD loaded SLNs were evaluated based on the dependent variables which were particle size, polydispersity index, zeta potential, entrapment efficiency, and cumulative % drug release for 24 h (Y1–Y5). The in vitro release study exhibited a sustained release of MTD from the SLNs up to 24 h. The optimal MTD loaded SLNs showed nanosized particles (256 nm) with EE% (52%), and an acceptable ZP value (−29.5 mV). Also, the optimized MTD-SLNs formulation was incorporated into Carbopol emulgel and investigated clinically for its effect against BV. Clinical studies recorded significant enhancement in therapeutic response of MTD from optimized SLNs vaginal emulgel formulation regarding the clinical treatment (p < .05) and low recurrence rate (p < .001) against the marketed product. In conclusion, our findings recommend that the fabricated MTD loaded SLNs vaginal emulgel have significant therapeutic effect in terms of BV management over commercially obtainable marketed vaginal gel (Metron®).http://dx.doi.org/10.1080/10717544.2021.1912211metronidazolesolid lipid nanoparticlesvaginal emulgelbacterial vaginosisclinical studies
collection DOAJ
language English
format Article
sources DOAJ
author Noha M. Badawi
Mona A. Elkafrawy
Rania M. Yehia
Dalia A. Attia
spellingShingle Noha M. Badawi
Mona A. Elkafrawy
Rania M. Yehia
Dalia A. Attia
Clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrence
Drug Delivery
metronidazole
solid lipid nanoparticles
vaginal emulgel
bacterial vaginosis
clinical studies
author_facet Noha M. Badawi
Mona A. Elkafrawy
Rania M. Yehia
Dalia A. Attia
author_sort Noha M. Badawi
title Clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrence
title_short Clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrence
title_full Clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrence
title_fullStr Clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrence
title_full_unstemmed Clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrence
title_sort clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrence
publisher Taylor & Francis Group
series Drug Delivery
issn 1071-7544
1521-0464
publishDate 2021-01-01
description The main focus of the current work was to design, evaluate and clinically compare the efficiency of novel metronidazole (MTD) loaded solid lipid nanoparticles (SLNs) vaginal emulgel with the marketed vaginal gel (Metron®) against Bacterial vaginosis (BV). Eight formulations were fabricated using 23 full factorial design and prepared by stearic acid and tween 80 as solid lipid and surfactant, respectively. Lipid and surfactant concentrations in addition to sonication amplitude were chosen as the independent variables (X1–X3). Then, the prepared MTD loaded SLNs were evaluated based on the dependent variables which were particle size, polydispersity index, zeta potential, entrapment efficiency, and cumulative % drug release for 24 h (Y1–Y5). The in vitro release study exhibited a sustained release of MTD from the SLNs up to 24 h. The optimal MTD loaded SLNs showed nanosized particles (256 nm) with EE% (52%), and an acceptable ZP value (−29.5 mV). Also, the optimized MTD-SLNs formulation was incorporated into Carbopol emulgel and investigated clinically for its effect against BV. Clinical studies recorded significant enhancement in therapeutic response of MTD from optimized SLNs vaginal emulgel formulation regarding the clinical treatment (p < .05) and low recurrence rate (p < .001) against the marketed product. In conclusion, our findings recommend that the fabricated MTD loaded SLNs vaginal emulgel have significant therapeutic effect in terms of BV management over commercially obtainable marketed vaginal gel (Metron®).
topic metronidazole
solid lipid nanoparticles
vaginal emulgel
bacterial vaginosis
clinical studies
url http://dx.doi.org/10.1080/10717544.2021.1912211
work_keys_str_mv AT nohambadawi clinicalcomparativestudyofoptimizedmetronidazoleloadedlipidnanocarriervaginalemulgelformanagementofbacterialvaginosisanditsrecurrence
AT monaaelkafrawy clinicalcomparativestudyofoptimizedmetronidazoleloadedlipidnanocarriervaginalemulgelformanagementofbacterialvaginosisanditsrecurrence
AT raniamyehia clinicalcomparativestudyofoptimizedmetronidazoleloadedlipidnanocarriervaginalemulgelformanagementofbacterialvaginosisanditsrecurrence
AT daliaaattia clinicalcomparativestudyofoptimizedmetronidazoleloadedlipidnanocarriervaginalemulgelformanagementofbacterialvaginosisanditsrecurrence
_version_ 1721456668275900416